+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dengue Vaccine Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Dengue Vaccine Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Dengue Vaccine Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6083662
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dengue Vaccine Market grew from USD 1.53 billion in 2024 to USD 1.72 billion in 2025. It is expected to continue growing at a CAGR of 12.02%, reaching USD 3.03 billion by 2030.

Dengue fever remains a formidable public health challenge, affecting millions across tropical and subtropical regions. With climate change broadening the habitat of Aedes mosquitoes, disease transmission has accelerated, prompting an urgent need for effective preventive solutions. In response, the global scientific community has intensified efforts to develop a safe, broadly protective vaccine. This executive summary distills the critical developments shaping that effort, synthesizing market dynamics, regulatory shifts, and emerging technological breakthroughs.

As we embark on this journey through the dengue vaccine landscape, we will examine the forces redefining research priorities and commercial strategies. We begin by highlighting the macro trends driving innovation, from advances in mRNA platforms to revamped public health policies. Next, we explore the evolving regulatory and tariff environments that impact production costs and supply chain resilience. We then analyze how refined segmentation frameworks reveal opportunities for targeted outreach and optimized resource allocation. Finally, we present actionable recommendations for industry leaders and conclude with an invitation to connect with Ketan Rohom, Associate Director, Sales & Marketing, to access the full market intelligence report.

Transformative Shifts in the Landscape

The dengue vaccine sector is undergoing a period of transformational change, driven by scientific breakthroughs and evolving stakeholder expectations. Traditional platforms, such as live attenuated and inactivated vaccines, have reached a maturity plateau, prompting innovators to embrace next-generation approaches. The advent of mRNA-based constructs, for example, offers rapid design cycles and the potential for multivalent serotype coverage. Simultaneously, recombinant subunit vaccines leveraging virus-like particles or protein scaffolds have demonstrated enhanced immunogenicity in clinical trials.

On the policy front, governments in endemic regions are adopting more proactive immunization schedules, integrating dengue vaccines into national programs. Public-private partnerships have flourished, channeling funds into local manufacturing initiatives that strengthen supply chains and reduce dependency on overseas production. Meanwhile, research institutes and biotech startups collaborate to refine novel adjuvants that boost vaccine efficacy and durability. Collectively, these shifts reflect a sector in which agility, collaboration, and technological prowess define competitive advantage.

Cumulative Impact of United States Tariffs 2025

As of early 2025, new U.S. tariffs on select vaccine components and raw materials have introduced additional cost pressures across the manufacturing value chain. Increased duties on specialized reagents and single-use bioreactor consumables have prompted vaccine producers to reassess supplier networks and negotiate longer-term agreements to lock in favorable pricing. Some manufacturers have begun relocating auxiliary production to tariff-exempt countries, thereby safeguarding access to critical inputs.

These measures also influence the pricing benchmarks for global tenders and bilateral procurement agreements. Import-dependent markets, particularly those in Africa and Southeast Asia, face the dual challenge of higher landed costs and currency volatility. In response, industry stakeholders are accelerating the adoption of alternative sourcing strategies, including expanded local fill-and-finish capabilities and cross-border licensure agreements. By forging alliances with regional partners, leading manufacturers aim to mitigate tariff-driven disruptions while preserving economies of scale.

Key Segmentation Insights

When examining vaccine uptake through the lens of patient age group, it becomes clear that adolescents aged 13 to 19 represent a pivotal cohort for school-based immunization drives, while adults between 20 and 45 years and those over 60 require tailored messaging to address workplace and eldercare environments. Infants up to six months and young children aged one to five years demand formulations optimized for early-life immunogenicity and simplified dosing schedules. In parallel, the rise of mRNA-based and DNA-based vaccines highlights a shift toward customizable platforms, although inactivated, live attenuated, and recombinant subunit options retain key roles in markets with established cold-chain infrastructures.

End-user segmentation underscores divergent procurement behaviors: private-sector clinics and pharmacies often favor premium-priced innovations with rapid delivery, whereas public-sector centers and government hospitals prioritize cost-effective solutions with long-term supply guarantees. Distribution channels further shape the landscape: government-supplied programs drive volume in remote areas, while offline settings such as hospitals and retail pharmacies meet urban demand, complemented increasingly by online pharmacy platforms. Dosage-form preferences-ranging from multi-dose vials for mass campaigns to single-dose formats and effervescent tablets-reflect efforts to optimize patient compliance and minimize wastage.

Manufacturing continues to evolve, with novel methods such as insect cell culture gaining traction alongside traditional egg-based and cell culture-based production. Market participants span the full spectrum from biotech startups pioneering platform technologies to established pharmaceutical firms leveraging global networks. Funding sources are equally diverse, encompassing government grants, private investments, philanthropic contributions, and even crowdfunding initiatives aimed at accelerating early-stage research.

Key Regional Insights

In the Americas, strong public health mandates and existing immunization infrastructure have fostered rapid pilot programs, particularly in regions where previous dengue outbreaks prompted heightened disease awareness. Latin American nations are extending school-based campaigns, while the United States evaluates adult immunization guidelines in high-risk territories.

Europe, the Middle East, and Africa present a mosaic of priorities: southern Europe and the Gulf Cooperation Council countries focus on traveler protection, whereas sub-Saharan Africa explores integration of dengue vaccines into broader vector-borne disease initiatives. Public-private partnerships in the Middle East are funding local fill-and-finish facilities to bolster regional self-sufficiency.

Asia-Pacific remains the epicenter of dengue research and deployment. Southeast Asian nations, including Indonesia and Thailand, are among the first to secure regulatory clearances for next-generation candidates. Meanwhile, South Asian markets are tailoring adolescent and pediatric vaccination schedules to address seasonal transmission peaks. Collaborative manufacturing hubs in India and Singapore are emerging as cornerstones of global supply, reinforcing the region’s strategic importance.

Key Companies Insights

Global vaccine developers span a diverse spectrum, from multinational corporations with expansive R&D pipelines to regional specialists focusing on tropical disease solutions. AstraZeneca, with its strong mRNA collaboration network, and Sanofi, renowned for its recombinant subunit expertise, both drive innovation in multivalent formulations. Similarly, GlaxoSmithKline and Pfizer leverage platform technologies to accelerate clinical development, while Johnson & Johnson and Merck apply their experience in adjuvant systems to enhance strain cross-protection.

Emerging players also shape the market: Bharat Biotech and Serum Institute of India lead local manufacturing in high-burden regions, tapping into cost-effective infrastructure. CureVac and Inovio propel mRNA and DNA vaccine frontiers, respectively, while CSL Limited and Takeda invest in regional fill-and-finish capacities to improve turnaround times. Biotech startups like Vabiotech and GeneOne renew focus on insect cell culture, and research entities collaborate with established firms to de-risk early-stage antigens. By balancing agility with scale, these participants collectively advance the global dengue vaccine agenda.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platform diversification, investing in both established vaccine types and emergent constructs such as mRNA and virus-like particles. Strengthening strategic partnerships with local fill-and-finish operators will reduce tariff exposure and improve supply reliability. Leaders ought to integrate advanced analytics into demand forecasting, enabling precise allocation of multi-dose vials versus single-dose or oral formulations based on real-time epidemiological data.

Engagement with health authorities from the earliest development phases can streamline regulatory approvals and align product profiles with national immunization calendars. Co-development agreements with research institutes and philanthropic organizations will mitigate financial risk, particularly in early clinical studies of novel adjuvants. Furthermore, premium pricing models should be balanced against tiered pricing strategies in lower-income markets to maintain access while preserving margins. Finally, digital platforms and telehealth partnerships can expand reach through online pharmacies, creating new revenue streams and supporting patient adherence.

Conclusion

The dengue vaccine landscape stands at a critical inflection point, driven by technological innovation, shifting regulatory frameworks, and evolving public health priorities. By aligning investment in next-generation platforms with robust local manufacturing partnerships and by tailoring strategies to segmented patient cohorts, companies can capture value while advancing global health objectives. Proactive tariff mitigation, coupled with data-driven distribution planning, will be essential to sustaining supply continuity and achieving broad vaccine coverage.

Market Segmentation & Coverage

This research report categorizes the Dengue Vaccine Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Adolescents
    • 13 to 19 Years
  • Adults
    • 20 to 45 Years
    • 45 to 60 Years
    • 60 Years and Above
  • Children
    • 1 to 5 Years
    • 6 to 12 Years
  • Infants
    • 6 to 12 Months
    • Up to 6 Months
  • DNA-Based Vaccine
  • Inactivated Vaccine
  • Live Attenuated
    • Multi-Serotype Vaccine
    • Single-Serotype Vaccine
  • mRNA-Based Vaccine
  • Recombinant Subunit Vaccine
    • Protein-Based
    • Virus-Like Particles
  • Private Sector
    • Pharmacies
    • Private Clinics
  • Public Sector
    • Community Health Centers
    • Government Hospitals
  • Research Institutes
  • Adults
  • Elderly
  • Pediatrics
  • Government Supply
  • Offline Pharmacies
    • Hospitals
    • Retail
  • Online Pharmacies
  • Injection
    • Multi-Dose Vial
    • Single-Dose Vial
  • Oral
    • Effervescent Tablets
    • Syrup
  • Novel Methods
    • Insect Cell Culture
  • Traditional Methods
    • Cell Culture-Based Production
    • Egg-Based Production
  • Biotech Startups
  • Large Pharmaceutical Firms
  • Research Entities
  • Crowdfunding
  • Government Grants
  • Not-For-Profit Organizations
  • Private Investments

This research report categorizes the Dengue Vaccine Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Dengue Vaccine Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AstraZeneca
  • Bharat Biotech
  • Bio Farma
  • Biological E. Limited
  • CSL Limited
  • CureVac AG
  • GeneOne Life Science, Inc.
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medigen Vaccine Biologics Corp.
  • Merck & Co., Inc.
  • Panacea Biotec
  • PaxVax, Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vabiotech

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dengue Vaccine Market, by Patient Age Group
8.1. Introduction
8.2. Adolescents
8.2.1. 13 to 19 Years
8.3. Adults
8.3.1. 20 to 45 Years
8.3.2. 45 to 60 Years
8.3.3. 60 Years and Above
8.4. Children
8.4.1. 1 to 5 Years
8.4.2. 6 to 12 Years
8.5. Infants
8.5.1. 6 to 12 Months
8.5.2. Up to 6 Months
9. Dengue Vaccine Market, by Vaccine Platform Type
9.1. Introduction
9.2. DNA-Based Vaccine
9.3. Inactivated Vaccine
9.4. Live Attenuated
9.4.1. Multi-Serotype Vaccine
9.4.2. Single-Serotype Vaccine
9.5. mRNA-Based Vaccine
9.6. Recombinant Subunit Vaccine
9.6.1. Protein-Based
9.6.2. Virus-Like Particles
10. Dengue Vaccine Market, by End-User
10.1. Introduction
10.2. Private Sector
10.2.1. Pharmacies
10.2.2. Private Clinics
10.3. Public Sector
10.3.1. Community Health Centers
10.3.2. Government Hospitals
10.4. Research Institutes
11. Dengue Vaccine Market, by Customer Type
11.1. Introduction
11.2. Adults
11.3. Elderly
11.4. Pediatrics
12. Dengue Vaccine Market, by Distribution Channel
12.1. Introduction
12.2. Government Supply
12.3. Offline Pharmacies
12.3.1. Hospitals
12.3.2. Retail
12.4. Online Pharmacies
13. Dengue Vaccine Market, by Vaccine Dosage Form
13.1. Introduction
13.2. Injection
13.2.1. Multi-Dose Vial
13.2.2. Single-Dose Vial
13.3. Oral
13.3.1. Effervescent Tablets
13.3.2. Syrup
14. Dengue Vaccine Market, by Manufacturing Process
14.1. Introduction
14.2. Novel Methods
14.2.1. Insect Cell Culture
14.3. Traditional Methods
14.3.1. Cell Culture-Based Production
14.3.2. Egg-Based Production
15. Dengue Vaccine Market, by Market Participants
15.1. Introduction
15.2. Biotech Startups
15.3. Large Pharmaceutical Firms
15.4. Research Entities
16. Dengue Vaccine Market, by Funding Source
16.1. Introduction
16.2. Crowdfunding
16.3. Government Grants
16.4. Not-For-Profit Organizations
16.5. Private Investments
17. Americas Dengue Vaccine Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Dengue Vaccine Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Dengue Vaccine Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. AstraZeneca
20.3.2. Bharat Biotech
20.3.3. Bio Farma
20.3.4. Biological E. Limited
20.3.5. CSL Limited
20.3.6. CureVac AG
20.3.7. GeneOne Life Science, Inc.
20.3.8. GlaxoSmithKline plc
20.3.9. Inovio Pharmaceuticals, Inc.
20.3.10. Johnson & Johnson
20.3.11. Medigen Vaccine Biologics Corp.
20.3.12. Merck & Co., Inc.
20.3.13. Panacea Biotec
20.3.14. PaxVax, Inc.
20.3.15. Pfizer Inc.
20.3.16. Sanofi
20.3.17. Serum Institute of India Pvt. Ltd.
20.3.18. Sinovac Biotech Ltd.
20.3.19. Takeda Pharmaceutical Company Limited
20.3.20. Vabiotech
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. DENGUE VACCINE MARKET MULTI-CURRENCY
FIGURE 2. DENGUE VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. DENGUE VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2024 VS 2030 (%)
FIGURE 24. GLOBAL DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. DENGUE VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. DENGUE VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DENGUE VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY 13 TO 19 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY 20 TO 45 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY 45 TO 60 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY 60 YEARS AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY 1 TO 5 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY 6 TO 12 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY 6 TO 12 MONTHS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY UP TO 6 MONTHS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DENGUE VACCINE MARKET SIZE, BY DNA-BASED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DENGUE VACCINE MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DENGUE VACCINE MARKET SIZE, BY MULTI-SEROTYPE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DENGUE VACCINE MARKET SIZE, BY SINGLE-SEROTYPE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DENGUE VACCINE MARKET SIZE, BY MRNA-BASED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DENGUE VACCINE MARKET SIZE, BY PROTEIN-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DENGUE VACCINE MARKET SIZE, BY VIRUS-LIKE PARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DENGUE VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DENGUE VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DENGUE VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DENGUE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DENGUE VACCINE MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DENGUE VACCINE MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DENGUE VACCINE MARKET SIZE, BY GOVERNMENT SUPPLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DENGUE VACCINE MARKET SIZE, BY RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DENGUE VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DENGUE VACCINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DENGUE VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DENGUE VACCINE MARKET SIZE, BY SINGLE-DOSE VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DENGUE VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DENGUE VACCINE MARKET SIZE, BY EFFERVESCENT TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DENGUE VACCINE MARKET SIZE, BY SYRUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DENGUE VACCINE MARKET SIZE, BY INSECT CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DENGUE VACCINE MARKET SIZE, BY CELL CULTURE-BASED PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL DENGUE VACCINE MARKET SIZE, BY EGG-BASED PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL DENGUE VACCINE MARKET SIZE, BY BIOTECH STARTUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL DENGUE VACCINE MARKET SIZE, BY LARGE PHARMACEUTICAL FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL DENGUE VACCINE MARKET SIZE, BY RESEARCH ENTITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL DENGUE VACCINE MARKET SIZE, BY CROWDFUNDING, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL DENGUE VACCINE MARKET SIZE, BY GOVERNMENT GRANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL DENGUE VACCINE MARKET SIZE, BY NOT-FOR-PROFIT ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL DENGUE VACCINE MARKET SIZE, BY PRIVATE INVESTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 149. CANADA DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 150. CANADA DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 151. CANADA DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 152. CANADA DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 153. CANADA DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 154. CANADA DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 155. CANADA DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 156. CANADA DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 157. CANADA DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. CANADA DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 159. CANADA DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 160. CANADA DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 161. CANADA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. CANADA DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 163. CANADA DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 164. CANADA DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 165. CANADA DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 166. CANADA DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 167. CANADA DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 168. CANADA DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 169. CANADA DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 170. CANADA DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 171. MEXICO DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. MEXICO DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 174. MEXICO DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 175. MEXICO DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 176. MEXICO DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 177. MEXICO DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 178. MEXICO DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 179. MEXICO DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. MEXICO DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 181. MEXICO DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 182. MEXICO DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 183. MEXICO DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. MEXICO DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 185. MEXICO DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 186. MEXICO DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 187. MEXICO DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 188. MEXICO DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 189. MEXICO DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 190. MEXICO DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 191. MEXICO DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 192. MEXICO DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 261. CHINA DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 262. CHINA DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 263. CHINA DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 264. CHINA DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 265. CHINA DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 266. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 267. CHINA DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 268. CHINA DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 269. CHINA DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 270. CHINA DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 271. CHINA DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 272. CHINA DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 273. CHINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. CHINA DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 276. CHINA DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 277. CHINA DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 278. CHINA DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 279. CHINA DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 280. CHINA DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 281. CHINA DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 282. CHINA DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 283. INDIA DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 284. INDIA DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 285. INDIA DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 286. INDIA DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 287. INDIA DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 288. INDIA DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 289. INDIA DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 290. INDIA DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 291. INDIA DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 292. INDIA DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 293. INDIA DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 294. INDIA DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 295. INDIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. INDIA DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 297. INDIA DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 298. INDIA DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 299. INDIA DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 300. INDIA DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 301. INDIA DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 302. INDIA DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 303. INDIA DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 304. INDIA DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 305. INDONESIA DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 306. INDONESIA DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 307. INDONESIA DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 308. INDONESIA DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 325. INDONESIA DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 326. INDONESIA DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 327. JAPAN DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 328. JAPAN DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 329. JAPAN DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 330. JAPAN DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 331. JAPAN DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 332. JAPAN DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 333. JAPAN DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 334. JAPAN DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 335. JAPAN DENGUE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 336. JAPAN DENGUE VACCINE MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 337. JAPAN DENGUE VACCINE MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 338. JAPAN DENGUE VACCINE MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 339. JAPAN DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 340. JAPAN DENGUE VACCINE MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 341. JAPAN DENGUE VACCINE MARKET SIZE, BY VACCINE DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 342. JAPAN DENGUE VACCINE MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 343. JAPAN DENGUE VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 344. JAPAN DENGUE VACCINE MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 345. JAPAN DENGUE VACCINE MARKET SIZE, BY NOVEL METHODS, 2018-2030 (USD MILLION)
TABLE 346. JAPAN DENGUE VACCINE MARKET SIZE, BY TRADITIONAL METHODS, 2018-2030 (USD MILLION)
TABLE 347. JAPAN DENGUE VACCINE MARKET SIZE, BY MARKET PARTICIPANTS, 2018-2030 (USD MILLION)
TABLE 348. JAPAN DENGUE VACCINE MARKET SIZE, BY FUNDING SOURCE, 2018-2030 (USD MILLION)
TABLE 349. MALAYSIA DENGUE VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 350. MALAYSIA DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 351. MALAYSIA DENGUE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 352. MALAYSIA DENGUE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 353. MALAYSIA DENGUE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 354. MALAYSIA DENGUE VACCINE MARKET SIZE, BY VACCINE PLATFORM TYPE, 2018-2030 (USD MILLION)
TABLE 355. MALAYSIA DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 356. MALAYSIA DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 357. MALAYSIA DENGUE VACCINE MARKET SIZE,

Companies Mentioned

  • AstraZeneca
  • Bharat Biotech
  • Bio Farma
  • Biological E. Limited
  • CSL Limited
  • CureVac AG
  • GeneOne Life Science, Inc.
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medigen Vaccine Biologics Corp.
  • Merck & Co., Inc.
  • Panacea Biotec
  • PaxVax, Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vabiotech

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dengue Vaccine Market by Vaccine Type, End User, Age Group, Vaccine Development Stage, Distribution Channel, Route of Administration, Technology, Patient Type - Global Forecast 2025-2030 - Product Image

Dengue Vaccine Market by Vaccine Type, End User, Age Group, Vaccine Development Stage, Distribution Channel, Route of Administration, Technology, Patient Type - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Dengue Vaccine Market Report 2025 - Product Image

Dengue Vaccine Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Dengue Vaccine Market Opportunities and Strategies to 2034 - Product Image

Dengue Vaccine Market Opportunities and Strategies to 2034

  • Report
  • 294 Pages
  • Global
From
Dengue Vaccine - Global Strategic Business Report - Product Image

Dengue Vaccine - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Vaccine Market Report by Technology, Patient Type, Indication, Route of Administration, Product Type, Treatment Type, End User, Distribution Channel, and Region 2025-2033 - Product Image

Vaccine Market Report by Technology, Patient Type, Indication, Route of Administration, Product Type, Treatment Type, End User, Distribution Channel, and Region 2025-2033

  • Report
  • 144 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.